Subthalamic nucleus deep brain stimulation induces functional deficits in norepinephrinergic neurotransmission in a Parkinson's disease model.

Autor: Statz M; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany., Weber H; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany., Weis F; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany., Kober M; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany., Bathel H; Institute of General Electrical Engineering, University of Rostock, 18059 Rostock, Germany., Plocksties F; Institute of Applied Microelectronics and Computer Engineering, University of Rostock, 18059 Rostock, Germany., van Rienen U; Institute of General Electrical Engineering, University of Rostock, 18059 Rostock, Germany; Department Life, Light and Matter, University of Rostock, 18059 Rostock, Germany; Department of Ageing of Individuals and Society, Interdisciplinary Faculty, University of Rostock, 18059 Rostock, Germany., Timmermann D; Institute of Applied Microelectronics and Computer Engineering, University of Rostock, 18059 Rostock, Germany., Storch A; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany; German Centre for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Gehlsheimer Straße 20, 18147 Rostock, Germany., Fauser M; Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany. Electronic address: mareike.fauser@med.uni-rostock.de.
Jazyk: angličtina
Zdroj: Brain research [Brain Res] 2024 Oct 15; Vol. 1841, pp. 149128. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1016/j.brainres.2024.149128
Abstrakt: Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is a successful treatment option in Parkinson's disease (PD) for different motor and non-motor symptoms, but has been linked to postoperative cognitive impairment.
Aim: Since both dopaminergic and norepinephrinergic neurotransmissions play important roles in symptom development, we analysed STN-DBS effects on dopamine and norepinephrine availability in different brain regions and morphological alterations of catecholaminergic neurons in the 6-hydroxydopamine PD rat model.
Methods: We applied one week of continuous unilateral STN-DBS or sham stimulation, respectively, in groups of healthy and 6-hydroxydopamine-lesioned rats to quantify dopamine and norepinephrine contents in the striatum, olfactory bulb and dentate gyrus. In addition, we analysed dopaminergic cell counts in the substantia nigra pars compacta and area tegmentalis ventralis and norepinephrinergic neurons in the locus coeruleus after one and six weeks of STN-DBS.
Results: In 6-hydroxydopamine-lesioned animals, one week of STN-DBS did not alter dopamine levels, while striatal norepinephrine levels were decreased. However, neither one nor six weeks of STN-DBS altered dopaminergic neuron numbers in the midbrain or norepinephrinergic neuron counts in the locus coeruleus. Dopaminergic fibre density in the dorsal and ventral striatum also remained unchanged after six weeks of STN-DBS. In healthy animals, one week of STN-DBS resulted in increased dopamine levels in the olfactory bulb and decreased contents in the dentate gyrus, but had no effects on norepinephrine availability.
Conclusions: STN-DBS modulates striatal norepinephrinergic neurotransmission in a PD rat model. Additional behavioural studies are required to investigate the functional impact of this finding.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: